Abstract
Because of the inverse association of cigarette smoking with the risk of Parkinson's disease, we performed a short-term, double-blind, randomized controlled trial of nicotine polacrilex resin gum in patients with this disease. Forty-eight subjects were randomly assigned to chew either nicotine gum or placebo gum three times at 2-h intervals, with evaluation of symptoms before and after the trial. The nicotine gum was reasonably well tolerated, but there were no substantial differences in Parkinson's disease symptoms between the two treatment groups.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Aged
-
Blood Pressure / drug effects
-
Central Nervous System Stimulants / administration & dosage
-
Central Nervous System Stimulants / adverse effects
-
Central Nervous System Stimulants / therapeutic use*
-
Chewing Gum
-
Double-Blind Method
-
Female
-
Humans
-
Male
-
Middle Aged
-
Nicotine / administration & dosage
-
Nicotine / adverse effects
-
Nicotine / analogs & derivatives*
-
Nicotine / therapeutic use
-
Parkinson Disease / physiopathology
-
Parkinson Disease / prevention & control*
-
Polymethacrylic Acids / administration & dosage
-
Polymethacrylic Acids / adverse effects
-
Polymethacrylic Acids / therapeutic use*
-
Polyvinyls / administration & dosage
-
Polyvinyls / adverse effects
-
Polyvinyls / therapeutic use*
-
Pulse / drug effects
-
Tobacco Use Cessation Devices
Substances
-
Central Nervous System Stimulants
-
Chewing Gum
-
Polymethacrylic Acids
-
Polyvinyls
-
Nicotine